The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
Open accessAbstract
BACKGROUND: We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy. METHODS: In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy. RESULTS: At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29). CONCLUSIONS: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov numbers, NCT00000620 for the ACCORD study and NCT00542178 for the ACCORD Eye study.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary composite major CV outcomes (nonfatal MI, nonfatal stroke or death from CV causes) were not reduced significantly in ACCORD (hazard ratio [HR] 0.90, p=0.16).”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes, an A1C ≤6.5% may be targeted to reduce the risk of CKD [Grade A, Level 1A (23)] and retinopathy [Grade A, Level 1A (21)], if they are assessed to be at low risk of hypoglycemia based on class of antihyperglycemic medication(s) utilized and the person's characteristics [Grade D, Consensus].”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The UK Prospective Diabetes Study randomly assigned 4209 patients with newly diagnosed type 2 diabetes to receive conventional (primarily diet) vs intensive (insulin, sulfonylurea, or, if overweight, metformin) treatment, with mean attained HbA1C of 7.9% vs 7.0%, respectively.36,37”
From Diagnosis and Treatment of Type 2 Diabetes in Adults (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Other options that can stabilize retinopathy include lifestyle intervention or bariatric surgery in persons with T2D or physical activity in persons with T1D.524–527”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [527]
Experimental — accuracy not yet measuredIn the citing paper
“Fenofibrate reduces the progression of diabetic retinopathy.413,414”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [414]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Davis MD, 1998, Invest Ophthalmol Vis Sci, 39, 233
- Cullen JF, 1964, Trans Ophthalmol Soc U K, 84, 281
- The ACCORD Study Group, 2007, Am J Cardiol, 99, 21i
- Ismail-Beigi F, 2010, Lancet, 375, 26
Cited by
Sorted by citations
Items 401–500 of 1,000
Emerging Insights and Interventions for Diabetic Retinopathy
Honasoge, A., Nudleman, E., Smith, M. E., & Rajagopal, R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1218-2 · Cited by 38
Diabetic and Retinal Vascular Eye Disease
Le, H.-G., & Shakoor, A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.02.004 · Cited by 37
Tuuminen, R., Sahanne, S., & Loukovaara, S. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12363 · Cited by 38
Hansen, M. J. B., Henriksen, J. E., Grauslund, J., & Pető, T. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13449 · Cited by 37
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 44
Selvaraj, K., Kuppusamy, G., Karri, V. V. S. R., Barauah, U. K., Ravisankar, V., & Jojo, G. M. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1280809 · Cited by 37
High-Density Lipoprotein Cholesterol in Age-Related Ocular Diseases
Betzler, B. K., Rim, T. H., Sabanayagam, C., Cheung, C. M. G., & Cheng, C. (2020) · Biomolecules · doi:10.3390/biom10040645 · Cited by 37
Correction: Choroid Sprouting Assay: An Ex Vivo Model of Microvascular Angiogenesis
Shao, Z., Friedlander, M. S. H., Hurst, C. G., Cui, Z., Pei, D. T., Evans, L. P., Juan, A. M., Tahiri, H., Duhamel, F., Chen, J., et al. (2013) · PLoS ONE · doi:10.1371/annotation/c6b85ec4-996d-4daf-863a-44260a888470 · Cited by 37
Pediatric Diabetic Retinopathy: Updates in Prevalence, Risk Factors, Screening, and Management
Lin, T., Gubitosi‐Klug, R., Channa, R., & Wolf, R. M. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01436-x · Cited by 38
Brunner, S. F., Höllerl, F., Schmid‐Kubista, K. E., Zeiler, F., Schernthaner, G., Binder, S., & Schernthaner, G.-H. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6520 · Cited by 35
Wang, Z., Pearsall, E., Ding, L., Cheng, R., Xu, X., & Ma, J. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-13396 · Cited by 36
Lipids, lipid-lowering therapy and diabetes complications
Valensi, P. E., & Picard, S. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.10.001 · Cited by 38
Type 2 diabetes and cardiac autonomic neuropathy screening using dynamic pupillometry
Lerner, A. G., Bernabé‐Ortiz, A., Ticse, R., Hernandez, A. G., Huaylinos, Y., Pinto, M. E., Málaga, G., Checkley, W., Gilman, R. H., Miranda, J. J., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.12752 · Cited by 38
Self-citationRisk Factors for Proliferative Diabetic Retinopathy in African Americans with Type 2 Diabetes
Penman, A. D., Hancock, H., Papavasileiou, E., James, M., Idowu, O., Riche, D. M., Fernandez, M., Brauner, S. C., Smith, S. O., Hoadley, S., et al. (2016) · Ophthalmic Epidemiology · doi:10.3109/09286586.2015.1119287 · Cited by 39
Xu, L., Xie, J., Chen, S., Chen, Y., Yang, H., Miao, M., Zhu, Z., Li, Y., Yu, C., & Xu, C. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000607 · Cited by 38
Hsu, Y.-J., Lin, C.-W., Cho, S.-L., Yang, W.-S., Yang, C.-M., & Yang, C.-H. (2020) · Antioxidants · doi:10.3390/antiox9080712 · Cited by 37
Zhang, X., Qiu, B., Wang, Q., Sivaprasad, S., Wang, Y., Zhao, L., Xie, R., Li, L., & Kang, W. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.779413 · Cited by 36
Agouridis, A. P., Rizos, C. V., Elisaf, M., & Filippatos, T. D. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.171 · Cited by 36
and The VADT Study Group, Azad, N., Agrawal, L., Emanuele, N., Klein, R., Bahn, G., & Reaven, P. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3199-7 · Cited by 36
Yun, J., Lim, T., Cha, S., Ahn, Y., Song, K., Choi, J. A., Kwon, J. W., Jee, D., Cho, Y. K., Park, Y., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.030 · Cited by 35
Boyd, S. R., Advani, A., Altomare, F., & Stockl, F. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.038 · Cited by 38
Role of the PPAR-α agonist fenofibrate in severe pediatric burn
Elijah, I. E., Børsheim, E., Maybauer, D. M., Finnerty, C. C., Herndon, D. N., & Maybauer, M. O. (2012) · Burns · doi:10.1016/j.burns.2011.12.004 · Cited by 36
Sabeti, F., Nolan, C. J., James, A. C., Jenkins, A. J., & Maddess, T. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16712 · Cited by 34
Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes
Vieira, C. P., Fortmann, S. D., Hossain, M., Longhini, A. L. F., Hammer, S. S., Asare‐Bediako, B., Crossman, D. K., Sielski, M. S., Adu-Agyeiwaah, Y., Dupont, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137230 · Cited by 34
Thiamine and diabetes: back to the future?
Beltramo, E., Mazzeo, A., & Porta, M. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01752-4 · Cited by 35
White, N. H., Pan, Q., Knowler, W. C., Schroeder, E. B., Dabelea, D., Chew, E. Y., Blodi, B., Goldberg, R. B., Pi-Sunyer, X., Darwin, C. H., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0860 · Cited by 34
Fenofibrate for diabetic retinopathy
Yamamoto‐Kataoka, S., Lois, N., Kawano, S., Kataoka, Y., Inoue, K., & Watanabe, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013318.pub2 · Cited by 36
Epidemiology, risk factors and management of paediatric diabetic retinopathy: Table 1
Sultan, M. B., Starita, C., & Huang, K. A. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300169 · Cited by 35
Brown, N. J. (2012) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2012.02.003 · Cited by 34
Sasongko, M. B., Wong, T. Y., Nguyen, T. T., Kawasaki, R., Jenkins, A. J., Shaw, J. E., Robinson, C., & Wang, J. J. (2012) · Diabetes · doi:10.2337/db11-1272 · Cited by 34
Hermans, M. P. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111407783 · Cited by 33
Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study
Massin, P., Pető, T., Ansquer, J.-C., Aubonnet, P., & for the MacuFEN Study Investigators (2014) · Ophthalmic Epidemiology · doi:10.3109/09286586.2014.949783 · Cited by 33
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33
Gao, H. X., Regier, E. E., & Close, K. L. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12377 · Cited by 36
Genotypes and Phenotypes: A Search for Influential Genes in Diabetic Retinopathy
Cabrera, A. P., Mankad, R. N., Marek, L., Das, R., Rangasamy, S., Monickaraj, F., & Das, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082712 · Cited by 34
Sun, S., Hisland, L., Grenet, G., Gueyffier, F., Cornu, C., Jaafari, N., & Boussageon, R. (2021) · Therapies · doi:10.1016/j.therap.2021.10.002 · Cited by 39
The Effect of Hyperlipidemia on the Course of Diabetic Retinopathy—Literature Review
Bryl, A., Mrugacz, M., Falkowski, M., & Zorena, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102761 · Cited by 33
Roy, S., Kim, D., Hernández, C., Simó, R., & Roy, S. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.08.010 · Cited by 33
Near-normalization of glucose and microvascular diabetes complications: data from ACCORD and ADVANCE
O’Connor, P. J., & Ismail‐Beigi, F. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810390545 · Cited by 35
Koh, K. K., Quon, M. J., Lim, S. K., Lee, Y., Sakuma, I., Lee, Y. H., Han, S. H., & Shin, E. K. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.023 · Cited by 33
Villena, J. E., Yoshiyama, C. A., Sánchez, J., Hilario, N. L., & Merin, L. M. (2011) · PubMed · Cited by 33
Shi, R., Guo, Z., Wang, F., Li, R., Zhao, L. Q., & Lin, R. (2017) · Current Eye Research · doi:10.1080/02713683.2017.1387669 · Cited by 33
Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?
Bejan‐Angoulvant, T., Cornu, C., Archambault, P., Tudrej, B. V., Audier, P., Brabant, Y., Gueyffier, F., & Boussageon, R. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.04.001 · Cited by 34
Diabetic Retinopathy in 2011: Further Insights From New Epidemiological Studies and Clinical Trials
Lamoureux, E. L., & Wong, T. Y. (2011) · Diabetes Care · doi:10.2337/dc11-0225 · Cited by 32
Tarantino, N. M., Santoro, F., Gennaro, L. D., Correale, M., Guastafierro, F., Gaglione, A., Biase, M. D., & Brunetti, N. D. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s95044 · Cited by 35
Long-Acting FGF21 Inhibits Retinal Vascular Leakage in In Vivo and In Vitro Models
Tomita, Y., Fu, Z., Wang, Z., Cakir, B., Cho, S. S., Britton, W. R., Sun, Y., Hellström, A., Talukdar, S., & Smith, L. E. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041188 · Cited by 32
Shah, S., Feher, M. D., McGovern, A. P., Sherlock, J., Whyte, M., Munro, N. M., Hinton, W., Gatenby, P. A. C., & de Lusignan, S. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108776 · Cited by 33
Lechner, J., Medina, R. J., Lois, N., & Stitt, A. W. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03073-x · Cited by 36
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes
Cariou, B., & Staels, B. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.954034 · Cited by 32
Primary prevention of diabetic retinopathy with fibrates: A retrospective, matched cohort study
Morgan, C. L., Owens, D. R., Aubonnet, P., Carr, E. S. M., Jenkins-Jones, S., Poole, C. D., & Currie, C. J. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-004025 · Cited by 31
Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy
Dhoot, D. S., & Avery, R. L. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0825-4 · Cited by 31
Mozetic, V., Leonel, L. F., Pacheco, R. L., Latorraca, C. D. O. C., Guimarães, T., Logullo, P., & Riera, R. (2019) · Trials · doi:10.1186/s13063-019-3868-4 · Cited by 31
PPARα activation directly upregulates thrombomodulin in the diabetic retina
Shiono, A., Sasaki, H., Sekine, R., Abe, Y., Matsumura, Y., Inagaki, T., Tanaka, T., Kodama, T., Aburatani, H., Sakai, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-67579-1 · Cited by 31
Ma, Y., Lin, C., Cai, X., Hu, S., Zhu, X., Lv, F., Yang, W., & Ji, L. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2102973 · Cited by 31
Hooper, P., Boucher, M. C., Cruess, A. F., Dawson, K. G., Delpero, W., Greve, M. D. J., Kožoušek, V., Lam, W., & Maberley, D. (2012) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2012.01.022 · Cited by 31
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00037-7 · Cited by 32
Association of ANRIL Expression with Coronary Artery Disease in Type 2 Diabetic Patients.
Rahimi, E., Ahmadi, A., Boroumand, M. A., Soltani, B. M., & Behmanesh, M. (2018) · PubMed Central · doi:10.22074/cellj.2018.4821 · Cited by 31
Farnier, M., Steinmetz, A., Retterstøl, K., & Császár, A. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.02.006 · Cited by 30
Jin, P., Peng, J., Zou, H., Wang, W., Fu, J., Shen, B., Bai, X., Xu, X., & Zhang, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123449 · Cited by 32
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 35
Akimoto, H., Tezuka, K., Nishida, Y., Nakayama, T., Takahashi, Y., & Asai, S. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.536 · Cited by 31
Diabetic Neuropathy of the Retina and Inflammation: Perspectives
Мухаррамовна, Б. Г., Oshitari, T., & Bikbov, M. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119166 · Cited by 32
Glineur, C., Gross, B. S., NEVE, B. P., Rommens, C., Chew, G. T., Martin‐Nizard, F., Rodríguez‐Pascual, F., Lamas, S., Watts, G. F., & Staels, B. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300665 · Cited by 30
One size does not fit all glycemic targets for type 2 diabetes
Pozzilli, P., Strollo, R., & Bonora, E. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12206 · Cited by 30
Mitochondrial Haplogroups Are Associated With Severity of Diabetic Retinopathy
Estopinal, C. B., Chocron, I. M., Parks, M. B., Wade, E. A., Roberson, R. M., Burgess, L. G., Brantley, M. A., & Samuels, D. C. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15149 · Cited by 31
Molsted, S., Tribler, J., Poulsen, P., & Snorgaard, O. (2012) · Health Education Research · doi:10.1093/her/cyr053 · Cited by 36
Pharmacological management of diabetic dyslipidemia
Filippatos, T. D., Florentin, M., Georgoula, M., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1263565 · Cited by 29
Diabetic Retinopathy –Incidence And Risk Factors In A Community Setting- A Longitudinal Study
Shani, M., Eviatar, T., Komaneshter, D., & Vinker, S. (2018) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2018.1487524 · Cited by 31
Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review
Elkjaer, A. S., Lynge, S. K., & Grauslund, J. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14377 · Cited by 31
Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review
Ntentakis, D. P., Correa, V., Ntentaki, A. M., Delavogia, E., Narimatsu, T., Efstathiou, N. E., & Vavvas, D. G. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06236-5 · Cited by 38
Prevalence of diabetic retinopathy in patients with recently diagnosed diabetes mellitus
Lee, K. M. C., & Sum, W. M. R. (2011) · Clinical and Experimental Optometry · doi:10.1111/j.1444-0938.2010.00574.x · Cited by 29
New approaches to the treatment of diabetic retinopathy
Porta, M., Maldari, P., & Mazzaglia, F. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01415.x · Cited by 29
Corona, G., Cipriani, S., Rastrelli, G., Sforza, A., Mannucci, E., & Maggi, M. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.07.004 · Cited by 29
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
Quartuccio, M., Buta, B. J., & Kalyani, R. R. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0215-z · Cited by 29
Recent advances in the applications of metabolomics in eye research
Chen, L., Gao, Y., Wang, L. Z., Cheung, N., Tan, G. S. W., Cheung, C. M. G., Beuerman, R. W., Wong, T. Y., Chan, E. C. Y., & Zhou, L. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.01.060 · Cited by 29
Review of the veteran affairs diabetes trial: Lessons learned
Tran, K., & Reaven, P. D. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09558-5 · Cited by 27
Zhang, M., Wu, J., Wang, Y., Wu, J., Hu, W., Jia, H., & Sun, X. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16830 · Cited by 31
Advances in the treatment of diabetic retinopathy.
El‐Asrar, A. M. A., & Al‐Mezaine, H. S. (2010) · PubMed · Cited by 28
Chowdhury, S. R., Thomas, R., Dunseath, G. J., Peter, R., Rees, A., North, R. V., Luzio, S. D., & Owens, D. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2203 · Cited by 28
Zhelev, Z., Peters, J., Rogers, M., Allen, M. J., Kijauskaite, G., Seedat, F., Wilkinson, E. C., & Hyde, C. (2023) · Journal of Medical Screening · doi:10.1177/09691413221144382 · Cited by 31
Ancel, P., Martin, J., Doukbi, E., Houssays, M., Gascon, P., Righini, M., Matonti, F., Svilar, L., Valmori, M., Tardivel, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512053 · Cited by 28
Plants used in the management of diabetic complications.
Dodda, D., & Ciddi, V. (2014) · Europe PMC (PubMed Central) · Cited by 28
The ORIGIN Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2238 · Cited by 29
The association of mental conditions with blood glucose levels in older adults with diabetes
Nguyen, H., Arcury, T. A., Grzywacz, J. G., Saldana, S. J., Ip, E. H., Kirk, J. K., Bell, R. A., & Quandt, S. A. (2012) · Aging & Mental Health · doi:10.1080/13607863.2012.688193 · Cited by 30
Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?
Hermans, M. P., & Fruchart, J. (2010) · Clinical Lipidology · doi:10.2217/clp.10.65 · Cited by 28
Betacellulin Induces Increased Retinal Vascular Permeability in Mice
Anand‐Apte, B., Ebrahem, Q., Cutler, A., Farage, E., Sugimoto, M., Hollyfield, J. G., & Folkman, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013444 · Cited by 28
Al-Janabi, A., Lightman, S., & Tomkins‐Netzer, O. (2018) · Eye · doi:10.1038/s41433-018-0066-7 · Cited by 29
Seok, H., & Soo, B. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.5.326 · Cited by 27
Lipid metabolites in the pathogenesis and treatment of neovascular eye disease
Stahl, A., Krohne, T. U., Sapieha, P. S., Chen, J., Hellström, A., Chew, E. Y., Holz, F. G., & Smith, L. E. H. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.194241 · Cited by 28
Does tight control of systemic factors help in the management ofdiabetic retinopathy?
Mohan, V., Rajalakshmi, R., & Prathiba, V. (2016) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.178146 · Cited by 29
Hooper, P., Boucher, M. C., Cruess, A. F., Dawson, K. G., Delpero, W., Greve, M. D. J., Kožoušek, V., Lam, W., & Maberley, D. (2017) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2017.09.027 · Cited by 25
Chung, Y.-R., Ha, K. H., Kim, H. C., Park, S. J., Lee, K., & Kim, D. J. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0137 · Cited by 27
Yang, Y., Zhou, J., Li, W. H., Zhou, Z., & Xia, X. B. (2021) · PeerJ · doi:10.7717/peerj.11817 · Cited by 27
Bonora, B. M., Albiero, M., Morieri, M. L., Cappellari, R., Amendolagine, F. I., Mazzucato, M., Zambon, A., Iori, E., Avogaro, A., & Fadini, G. P. (2021) · Diabetologia · doi:10.1007/s00125-021-05532-1 · Cited by 27
Evidence-Based Treatment of Diabetic Macular Edema
Barham, R., Rami, H. E., Sun, J. K., & Silva, P. S. (2017) · Seminars in Ophthalmology · doi:10.1080/08820538.2016.1228388 · Cited by 27
May, M., Framke, T., Junker, B., Framme, C., Pielen, A., & Schindler, C. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819891886 · Cited by 27
Tolonen, N., Hietala, K., Forsblom, C. M., Harjutsalo, V., Mäkinen, V., Kytö, J., Summanen, P. A., Thorn, L. M., Wadén, J., Gordin, D., et al. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12111 · Cited by 27
Self-citationFunctional diabetic retinopathy: A new concept to improve management of diabetic retinal diseases
Rai, B. B., Maddess, T., & Nolan, C. J. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.11.010 · Cited by 26
Stegemann, S. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1472571 · Cited by 26
Saini, D. J. B., Sivakami, R., Venkatesh, R., Raghava, C. S., Dwarkanath, P. S., Anwer, T. M. K., Smirani, L. K., Ahammad, S. H., Udayaraju, P., Hossain, M. A., et al. (2023) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2023.105180 · Cited by 26
Metadata
- Authors
- The ACCORD Study Group and ACCORD Eye Study Group
- Corresponding author
- The ACCORD Study Group and ACCORD Eye Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-15
- Volume
- 363
- Issue
- 3
- Pages
- 233-244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4026164
- OpenAlex
- W2219384223
- Semantic Scholar
- 9a607a3bfd9432a917f703d573fdaa1052647711
- Cited by
- 1,311
- References
- 36
- Citations by year
- 2026: 54 · 2025: 60 · 2024: 66 · 2023: 86 · 2022: 73 · 2021: 94 · 2020: 96 · 2019: 57 · 2018: 78 · 2017: 87 · 2016: 82 · 2015: 84 · 2014: 74 · 2013: 81 · 2012: 93
- FWCI
- 111.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Massachusetts Medical Society
- Omron Healthcare
- Bayer HealthCare
- Daiichi-Sankyo
- Novo Nordisk
- Servier
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, Z99 EY999999, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Heart, Lung, and Blood Institute (N01- HC-95181, R01HL073030, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Eye Institute (ZIAEY000410)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic retinopathy, retinopathy progression, type 2 diabetes, tight glycemic control, HbA1c, fenofibrate, simvastatin, dyslipidemia, blood pressure control, laser photocoagulation, vitrectomy, cardiovascular risk reduction, combination therapy, Early Treatment Diabetic Retinopathy Study
- MeSH terms
- Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Drug Therapy, Combination, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Fenofibrate, Disease Progression, Simvastatin, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
